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Abstract
Background: The amount and quality of dietary fatty acids can modulate the fat metabolism.
Objective: This dietary intervention is based on the different metabolic pathways of long-chain
saturated fatty acids (LCFA), which are mostly stored in adipocytic triacylglycerols, medium-chain
fatty acids (MCFA) which are preferentially available for hepatic mitochondrial β-oxidation and n-
3 long-chain polyunsaturated fatty acids (n-3 LCPUFA) suggested to modulate fat oxidation and
storage by stimulating the peroxisomal β-oxidation. Combined dietary MCFA and n-3 LCPUFA
without LCFA may synergistically stimulate fatty acid oxidation resulting in blood lipid clearance
and LCFA release from adipocytes.
Design:  In a short term, parallel, randomized, double-blind trial effects on the fatty acid
metabolism of 10 healthy volunteers (Body Mass Index 25–30) of a formula containing 72% MCFA
and 22% n-3 LCPUFA without LCFA (intake: 1.500 kcal/day; fat: 55.5% of energy) were measured
in comparison to an isoenergetic formula with equal fat amount and LCFA dominated lipid profile.
Results: The plasma triacylglycerol (p < 0.1) and cholesterol (p < 0.05) content decreased in the
test group. The n-3/n-6 LCPUFA (≥ C 20) ratio increased (p < 0.0001) after 4 days treatment. The
LCFA content was similar in both groups despite missing LCFA in the test formula indicating LCFA
release from adipocytes into the plasma. Both groups significantly reduced body weight
considerably 4 kg (p < 0.01) and fat mass up to 50% of weight loss (p < 0.05).
Conclusion: Combined dietary 72% MCFA and 22% n-3 LCPUFA without LCFA stimulate the
fatty acid oxidation and release from adipocytes without affecting any safety parameters measured.
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Introduction
Dietary long-chain saturated fatty acids (LCFA; ≥ 16 car-
bon atoms) are an important nutritive energy source
which can be strictly incorporated into the adipocytic tri-
acylglycerol stores dominating the fatty acid composition
of adipose tissue [1]. In contrast, medium-chain fatty
acids (MCFA; 8–14 carbon atoms) as well as long-chain
polyunsaturated fatty acids (n-3 LCPUFA; ≥ 18 carbon
atoms) are limited storable and follow different pathways
of digestion and metabolism [2].
Triacylglycerols containing fatty acids with more than 12
carbon atoms must be hydrolyzed in the intestinal lumen
before absorption. In the enterocytes they will be re-syn-
thesized to triacylglycerols and preferentially used for the
formation of chylomicrons [3,4]. From the chylomicrons
LCFA are released by serum lipases to be metabolized by
tissue or stored in the adipocytes.
Triacylglycerols containing MCFA can directly be
absorbed without hydrolysis and preferentially trans-
ported through the portal venous system to the liver. On
the hepatocellular level, the carnitine acyltransferase,
which is the enzyme system necessary for LCFA transport
across the inner mitochondrial membrane is not required
for MCFA [5]. Thus, MCFA are more available for the
mitochondrial β-oxidation whereas most LCFA are incor-
porated into triacylglycerols in the hepatocyte. As MCFA
bypasses the adipose tissue lipoprotein lipase-regulated
metabolic pathway of LCFA the lipid deposition into adi-
pocytes may be limited by dietary MCFA intervention [6].
Additionally, it has already been shown that dietary inter-
vention with MCFA increased thermogenesis [7] and
endogenous oxidation of LCFA [8,9].
Also, the metabolic pathway of n-3 LCPUFA differs from
that of LCFA. Data from animal [10] and human studies
[11] suggest that n-3 LCPUFA may modulate the meta-
bolic balance between fat oxidation and storage. Schulz
and colleagues could demonstrate that n-3 LCPUFA can
stimulate the peroxisomal β-oxidation resulting in an
increased basal fatty acid oxidation [12].
Therefore we hypothesized that a MCFA and n-3 LCPUFA
rich but virtually LCFA free diet may result in a stimula-
tion of the total fatty acid oxidation accompanied by an
increased endogenous oxidation of LCFA. This might
result in lipid blood clearance and LCFA release from
adipocytes.
To prove this hypothesis, a placebo controlled study was
designed to investigate the short term effect of a fat rich
but hypoenergetic experimental diet combining MCFA
and n-3 LCPUFA on plasma fatty acid profile and fat
metabolism.
Subjects and Methods
Experimental Protocol
Ten healthy volunteers with a body mass index (BMI)
between 25–30 were enrolled in the study. The most rele-
vant characteristics of the subjects are shown in Table 1.
The intervention was planned as a hypoenegetic diet.
Daily 800 ml of a ready to use formula drink (1200 kcal)
was administered. During the intervention it was not
allowed to add dietary fat but 300 kcal carbohydrates up
to a total energy intake of app. 1500 kcal/ day.
The two test formulas contained 55.5 % of total energy as
fat. The fat blend of the experimental formula was nearly
free of LCFA (sum of palmitic acid and stearic acid 1%)
but contained 72 % MCFA and 22 % n-3 LCPUFA of total
fat. The fat blend of the placebo was composed from veg-
etable oils with a LCFA dominated lipid profile. The for-
mulas were vitamin, mineral and fiber supplemented. The
composition and the fatty acid profile of the formulas are
shown in Table 2.
The trial was performed as prospective, randomized, dou-
ble-blind and placebo controlled study with a parallel
group design. The study protocol was approved by the
local Ethical Committee and written consent was achieved
from all volunteers.
Table 1: Clinical and para-clinical characteristics of subjects at the study entrance
Group1 Test Formula Placebo Formula
N5 5
Age (years) 43.2 ± 16.1 44.1 ± 15.6
Body weight (kg) 91.8 ± 12.2 80.9 ± 10.5
Fat mass (kg) 17.8 ± 6.4 18.8 ± 6.1
Body mass index 28.6 ± 2.5 26.2 ± 1.9
Plasma triacylglycerol (mg/dl) 233 ± 58 205 ± 55
Plasma cholesterol (mg/dl) 181 ± 84 129 ± 80
1 no significant differences according to t-testLipids in Health and Disease 2003, 2 http://www.lipidworld.com/content/2/1/10
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At enrolment, the volunteers were randomly allocated to
one of the two formula groups. The last day before starting
the diet was defined as day 0 and the first day of using the
formula was defined as study day 1. The intervention
period was 15 days.
At day 0, 4, 7, 9, 11 and 15 20 ml venous blood was
obtained, the plasma separated and stored at -20°C until
analysis. Urine was collected for 24 hours and a sample of
100 ml was separated from the pooled 24 hours urine.
The sample was stored at -20°C until analysis.
At days 0, 4, 7, 9, 11 and 15 body weight and at day 0 and
15 the fat mass was determined. The formula assessment
of tolerance was tested by a day to day questionnaire
focused on feeling of satiation and abdominal symptoms
using a five point scale.
Analytical Measurements
The body weight was determined in kg. The fat mass
expressed as percent of body weight was measured by
body impedance analysis (BIA) using the Data Input
2000–1 Body Impedance Analysis System (Data Input,
Frankfurt a.M., Germany).
The plasma of the blood samples were separated by cen-
trifugation 3360 × g for 10 min. In the plasma the concen-
trations of glucose, cholesterol, urea and triacylglycerol
were measured and the fatty acid profile in the different
lipid classes was determined. Additionally, the activity of
liver enzymes (γ glutamate transaminase (GGT),
Table 2: Nutrient and fatty acid composition of the high fat formula combine 72% MCFA and 22% n-3 LCPUFA without LCFA and 
placebo
Composition Test Formula Placebo Formula
Macronutrients (per 100 ml): gram kcal energy% gram kcal energy%
Protein 7.5 30.0 19.5 7,5 30.0 19.5
Carbohydrates 9.4 37.6 25.0 9.4 37.6 25.0
Fat 1 9.2 82.8 55.5 9.2 82.8 55.5
Cholesterol > 0.001 -
Total enegy 150.4 100 150.4 100
Fibre 2.0 - - 2.0 - -
Specific Fatty Acids (wt%)
C 8:0 44.8 1.0
C 10:0 27.3 0.6
C 14:0 0.2 0.8
C 16:0 palmitic acid 0.8 29.6
C 16:1 n-7 0.2 0.1
C 17:0 0.1 0.1
C 17:1 n-7 0.1 -
C 18:0 stearic acid 0.2 4.3
C 18:1 n-9 oleic acid 0.9 33.4
C 18:2 n-6 linoleic acid 2.1 27.9
C 18:3 n-6 γ-linolenic acid 0.1 -
C 18:3 n-3 α-linolenic acid 0.4 0.3
C 18:4 n-3 1.0 -
C 20:4 n-6 arachidonic acid 0.8 -
C 20:5 n-3 eicosapentaenoic acid 14.4 -
C 22:4 n-6 0.1 -
C 22:5 n-3 0.1 -
C 22:6 n-3 docosahexaenoic acid 5.6 -
C24:0 - 0.1
1 fatty acids with C 6–8 carbon atoms length = 8.3 kcal/g; fatty acids with C16–18 carbon atoms length = 9.2 kcal/g : 1 kcal difference between test 
and placebo and 50 kcal difference/dayLipids in Health and Disease 2003, 2 http://www.lipidworld.com/content/2/1/10
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glutamate oxalacetate transaminase (GOT), glutamate
pyruvate transaminase (GPT) and the activity of the pan-
creatic lipase were determined. In the urine the concentra-
tions of creatinine, urea and ammonia nitrogen were
measured. With exception of the fatty acid profile all
measurements were performed according to the standard
methods of the University Clinic Giessen performed with
Roche/Hitachi tests using the Sysmex-XE3000 and
SE9000 Hitachi-Roche analysis systems (Roche, Basel,
Switzerland): glucose and urea were determined by UV-
tests, cholesterol, triacylglycerols, lipase, and ammonia
nitrogen were analyzed by enzymatic color assays, GOT
was determined according to the Sysmex test (IFCC/
SM94) without pyridoxalphosphate, GPT according to the
Sysmex test (ALT/GPT IFCC) with pyridoxalphosphate,
and GGT with GGT Szasz liquid, creatinine was deter-
mined by the Jaffe method.
The fatty acid profile of blood plasma was determined by
fatty acid methylester (FAME) analysis. Total lipids of the
supernatant were extracted according to Bligh and Dyer
[13]. For derivatization, an aliquot of 3 mg total lipid
extract was resolved in 2 ml methanol/hexane (v/v) 4:1
plus pyrogallol and was methylated with 200 µl acetylclo-
ride at 100°C for 1 hour; 5 ml 6% K2CO3 was added and
centrifuged for 10 min at 2200 × g according to Lepage
[14]. The upper hexane phase containing the FAME was
removed and dried with Na2SO4. The FAME were ana-
lyzed by capillary gas-liquid chromatography on a LS 32
Varian Chrompack system (Varian Chrompack, Middel-
burg, The Netherlands), as previously described by Kohn
et al. [15].
Statistical Analysis
Data are given as mean ± standard deviation. Intra-group
comparisons (measurement day 15 vs. 0 and inter-group
comparisons between the two tested groups were per-
formed parametrically with the one-sided paired and with
the one-sided unpaired t-test, respectively. The tolerance
data on satiation and abdominal symptoms (85 point
scale) were analyzed by contingency table analysis. As
software Statview 4.5 (SAS Inc.) and SPSS 11.0 (SPSS Inc.)
were used. P < 0.05 was considered as statistically
significant.
Results
The most relevant characteristics of the subjects of the two
groups indicated no significant differences (Table 1).
In the test group the plasma triacylglycerol content
decreased after 15 days of dietary intervention from 180.6
± 84.19 mg/dl at day 0 to 103.6 ± 13.9 mg/dl at day 15
with a clear tendency (p < 0.1) in contrast to the placebo
group with less decrease of 129.0 ± 80.1 mg/dl pre- to
116.6 ± 59.0 mg/dl post-treatment (p = 0.244) (Figure 1).
Furthermore, the cholesterol concentration decreased
from 233.0 ± 58,0 mg/dl at day 0 to 188.4 ± 36.4 mg/dl in
the test group and from 204.8 ± 55.3 mg/dl at day 0 to
182.6 ± 38.5 mg/dl at day 15 significantly (p < 0.05) (Fig-
ure 1).
The fatty acid profile of plasma reflected the dietary intake
not always. The concentration of biochemical blood fat
indicators, like oleic acid (C 18:1 n-9) decreased slightly
14.0 ± 11.4% in the test group but not in the placebo
group. Although LCFA were missed in the test formula the
plasma content of prominent LCFA fatty acids, e.g. stearic
acid (C 18:0) (Figure 2), was similar comparing both
groups with a decline of 9.8 ± 6.5% % in the test group (p
< 0.05) and 13.0 ± 11.7% (p < 0.05) in the control group
with no significant group differences during the treatment
period. Due to the fact that there is 0.8 wt% arachidonic
Table 3: Safety parameters of venous blood and 24 hours urine after 15 days of dietary intervention with the high fat formula combine 
72% MCFA and 22% n-3 LCPUFA without LCFA and placebo
Test Formula Placebo Formula
Parameter Day 0 Day 15 Day 0 Day 15 Physiological Values1
plasma-glucose (mg/dl) 101.4 ± 9.7 98.4 ± 5.5 95.4 ± 10.8 87.0 ± 12.3 60–100
GGT (U/l) 18.2 ± 9.4 11.8 ± 5.0 11.2 ± 4.9 9.4 ± 3.7 ≤ 16/122
GPT (U/l) 17.6 ± 11.2 14.4 ± 8.2 10.8 ± 3.2 11.4 ± 3.7 ≤ 23/192
GOT (U/l) 11,0 ± 3.0 11,2 ± 3,1 10.6 ± 1.1 11.6 ± 1.1 10–50
Lipase (U/l) 28.8 ± 4.0 23.2 ± 3.9 38.2 ± 21.4 24.8 ± 4.6 ≤ 190
urine-creatinine (mg/dl) 82.8 ± 35.4 70.0 ± 47.7 80.0 ± 47.4 97.6 ± 78.1 ≤ 52/922
urine-creatinine (g/24 h) 2.2 ± 0.4 1.8 ± 0.7 1.5 ± 0.7 1.7 ± 0.4 1–2
plasma-urea (mg/dl) 34.2 ± 6.2 24.8 ± 6.3 28.2 ± 6.1 26.6 ± 5.2 10–50
urine-Urea (mg/dl) 1443.0 ± 531.4 810.6 ± 295.8 1220.6 ± 506.8 1192.8 ± 718.6 700–1300
urine-urea (g/24 h) 40.5 ± 6.1 27.1 ± 10.9 26.3 ± 12.6 20.5 ± 3.9 20
1 normal physiological values for adults according to Müller (37) 2 (man / woman)Lipids in Health and Disease 2003, 2 http://www.lipidworld.com/content/2/1/10
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acid (20:4 n-6) in the test formula and nil in the placebo
the arachidonic acid plasma level increased 32 ± 18.9 %
pre- to post-treatment significantly (p < 0.05) in the test
group and increased slightly 18 ± 13.5 % in the placebo
group (Figure 2). Likewise, the concentration of 14.4 wt%
n-3 eicosapentaenoic acid (C 20:5 n-3) in the test formula
and nil in the placebo was reflected by a significant
increase from 0.7 ± 0.2 wt% in the test group at day 0 to
10.8 ± 3.4 wt% at day 15 (p < 0.01), in contrast to the pla-
cebo group with a decrease from 0.8 ± 0.3 wt% at day 0 to
0.5 ± 0.16 wt% at day 15 with a significant difference
between both groups (p < 0.0001). After intervention
linoleic acid (C18:2 n-6) decreased in the test group with
32 ± 13.2 % but not in the placebo with 4.3 ± 19.0%
decline. Concerning this the difference between both
groups at day 15 was significant (p < 0.003).
Consequently, the n-3 to n-6 LCPUFA ratio (≥ 20 carbon
atoms chain length) increased in the test group signifi-
cantly (p < 0.0001) compared to the placebo intervention
shown in Figure 3 as a time course profile at day 0, 4, 7, 9,
11 and 15 of dietary treatment. Comparing both groups,
this alteration of plasma fatty acid composition was
already pronounced at day 4 (p = 0.0001) but the maxi-
mum effect was observed at day 15 in the test group.
Furthermore, several safety parameters during the inter-
vention were evaluated (Table 3). In both groups the
plasma glucose-level decreased within a physiologic
range. Neither in the placebo nor in test group any signif-
icant alterations on liver enzyme activities GGT, GOT,
GPT, pancreatic lipase-activity in the plasma, urinary cre-
atinine, and urea concentration in plasma and urine could
be detected. The compliance, tolerance and acceptance
evaluated in both groups was always good (data not
Decrease in plasma triacylglycerol and cholesterol after 15 days of dietary intervention with the high fat formula combine 72%  MCFA and 22% n-3 LCPUFA without LCFA and placebo Figure 1
Decrease in plasma triacylglycerol and cholesterol after 15 days of dietary intervention with the high fat formula combine 72% 
MCFA and 22% n-3 LCPUFA without LCFA and placebo.
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shown). Both groups showed a significant reduction of
body weight (p < 0.01) after 15 days treatment of 3.9 ± 1.5
kg in the test group and 3.8 ± 0.7 kg in the placebo group
due to the hypoenergetic intake. A loss of 1.8 ± 1.3 kg fat
mass after treatment could be detected in the test group
and a reduction of 1.3 ± 0.7 kg in the placebo group. The
loss of fat mass in both groups was significant (p < 0.05)
but the difference between the groups was not (p = 0.472)
(Figure 4).
Discussion
It is a widely accepted model of nutrient balance that the
metabolic handling of fat energy is likely to induce a pos-
itive energy balance mainly because of the inability of die-
tary fat to promote fat oxidation [16,17]. Indeed several
studies suggest that dietary fat intake and genotype
interact to regulate fat deposition [18,19]. It is an open
question, however, whether it is possible to affect the fatty
acid profile in the blood plasma by stimulating the fatty
acid oxidation with an experimental high fat formula con-
taining MCFA in combination with n-3 LCPUFA but with-
out LCFA. Due to its unique absorption and metabolic
characteristics, MCFA oil, consisting of saturated fatty
acids with 8–12 carbons, has been used therapeutically
since the 1950s in the treatment of fat malabsorption,
cystic fibrosis, epilepsy, weight control and to increase
exercise performance. Dietary n-3 LCPUFA on the other
side have been identified to influence the serum and red
blood cell membrane fatty acid composition [20] and to
stimulate the peroxisomal β-oxidation [21] resulting in an
increased basal lipid oxidation.
Furthermore, it has been shown that n-3 LCPUFA are an
environmental factor in the regulation of body mass
Alterations of plasma concentration of stearic acid and arachidonic acid at day 0 and day 15 of dietary intervention with the  high fat formula combine 72% MCFA and 22% n-3 LCPUFA without LCFA and placebo Figure 2
Alterations of plasma concentration of stearic acid and arachidonic acid at day 0 and day 15 of dietary intervention with the 
high fat formula combine 72% MCFA and 22% n-3 LCPUFA without LCFA and placebo.
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reduction [11]. Especially, eicosapentaenoic acid has been
suggested to induce the peroxisome proliferator-activated
receptor gamma-1 as a key regulator of adipocytes differ-
entiation, lipid metabolism and insulin resistance [22].
Thus, both MCFA and dietary lipids containing n-3 LCP-
UFA are candidates to stimulate the hepatocellular β-oxi-
dation. The results of the present short term intervention
study indicate that a combination of MCFA and n-3 LCP-
UFA but missing LCFA effected a significant reduction of
total plasma triacylglycerols probably due to an increased
β;-oxidation of fatty acids. The extent of this reduction was
higher than it could be suspected from the individual
MCFA or LCPUFA implications on lipid oxidation alone
suggesting synergetic effects. Previous Studies in animals
[23] and with infants [24] suggested that dietary n-3 LCP-
UFA could decrease the hepatic excretion of cholesterol
and biliary cholesterol nucleation time in obese women
[25].
In the present trial the cholesterol concentration
decreased in both groups due to the cholesterol free diet
with no significant differences between the groups.
The study also showed a specific effect of the test formula
on the plasma fatty acid pattern in comparison to the con-
trol. Dietary n-6 and n-3 fatty acids have opposing physi-
ological functions concerning homeostasis, normal
development of organs and tissues, inflammation and
mental health [26]. On condition that the normal western
diet is unbalanced in the n-3 to n-6 fatty acid ratio, it
might be necessary to decrease the intake of n-6 fatty acids
and increase the n-3 fatty acid intake. Tissue arachidonic
acid pools originate from the diet and from the hepatic
Alterations of plasma concentration of the n-3/n-6 LCFA ratio (≥ C 20) at day 0, 4, 7, 9, 11 and 15 days of dietary intervention  with the high fat formula combine 72% MCFA and 22% n-3 LCPUFA without LCFA and placebo Figure 3
Alterations of plasma concentration of the n-3/n-6 LCFA ratio (≥ C 20) at day 0, 4, 7, 9, 11 and 15 days of dietary intervention 
with the high fat formula combine 72% MCFA and 22% n-3 LCPUFA without LCFA and placebo.
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and extrahepatic desaturation-elongation of dietary lino-
leic acid. Particularly during fasting linoleic acid is an
important substrate (27). To affect the n-3 to n-6 ratio
shift the experimental fat blend contains sufficient
amounts of α-linolenic acid which daily requirement is
1.5 g C18:3 n-3/day [27,28], but less linoleic acid com-
pared to the placebo (Table 2). Arachidonic acid increased
in the test group and the essential linoleic acid concur-
renly decreased, eicosapentaenoic acid and docosahexae-
noic acid (C 22:6 n-3) increased (not shown) implying a
significant increase of the n-3 to n-6 LCPUFA ratio in the
test group compared to the control. This dietary influence
on the plasma fatty acid profile was already pronounced
at day 4, although the maximum effect was observed at
day 15.
Several studies with comparable fish oil supplementa-
tions indicated significant eicosapentaenoic acid and
docosahexaenoic acid demonstrated without extensive
alterations of total plasma fatty acid profile e.g. linoleic
acid was not affected [29,30]. In our study however, the
essential linoleic acid decreased in the test group suggest-
ing that MCFA and LCPUFA without LCFA provokes a
rapid blood clearance and pronounced increase of n-3/n-
6 ratio.
The necessary requirement for linoleic acid is 10 g/day
[27,28]. In fact, the reduction of the linoleic acid pro-
voked by the test fat blend is irrelevant during a short term
treatment because of physiologic reserves in the fat tissue
but may be questionable for long term usage. The meta-
bolic outcome during a long term treatment have to be
shown in further investigations.
To maintain human health and to support weight control
efforts a variety of dietary concepts are discussed that dif-
fer exceptionally in the macronutrient content and
infringe nutritional guidelines. As the administration of a
high fat diet with MCFA may imply the risk of liver injury
or an unbalanced glucose-protein metabolism [31]. On
this matter several physiological safety parameters were
evaluated. Neither significant physiological effects on
parameters for liver and kidney disorders (liver enzymes
activities in the plasma and creatinine concentration in
the urine) nor indicators of muscle decomposition (urea
concentration in the urine) or pancreas injury values
(lipase-activity in the plasma) could be detected. In
contrast to observations that LCPUFA could increase the
basal glucose level of plasma [32], the plasma glucose-
level of both test groups decreased within the physiologi-
cal range. In summary, these data indicate that the exper-
imental formula is safe concerning glucose metabolism,
protein digestion, liver and kidney function.
With respect to acceptance of hypoenergetic diets the sub-
jective feeling of satiety is always relevant. Carbohydrates
may play a greater role for the duration of satiety than
does fat but several studies suggested that MCFA are
important for other aspects of the control of food intake,
especially in satiation at the next meal [33]. In this short
term intervention all volunteers reported about their
satiety with both formulas possibly due to the high fat
content of the trial products.
Adult obesity is a health hazard because of its association
with numerous metabolic complications [34], but also
childhood obesity is the basis of coronary heart disease
risk and mortality in adulthood [35]. From studies in
post-obese individuals it is well known that these individ-
uals normally have low rates of fat oxidation that may
explain their risk to regain weight [36]. Additionally, it has
Loss in fat mass after 15 days of dietary intervention with the  high fat formula combine 72% MCFA and 22% n-3 LCPUFA  without LCFA in comparison to placebo shown as body  impedance BIA Figure 4
Loss in fat mass after 15 days of dietary intervention with the 
high fat formula combine 72% MCFA and 22% n-3 LCPUFA 
without LCFA in comparison to placebo shown as body 
impedance BIA.
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been postulated that weight loss distinct from energy
restriction is associated with improvements in serum lipid
levels. In this present study the fat mass reduced signifi-
cantly in the test group but also in the control group. In
contrast to the altered n-3 to n-6 LCPUFA ratio in plasma
in the test group, the concentration of storage fatty acids
like palmitic acid (C 16:0) (not shown) and stearic acid
remained in the homeostasis despite missing LCFA in the
test formula indicated a LCFA release from adipocytes.
Therefore, the rapid clearance of blood fat induced by an
increased stimulation of hepatocytic β-oxidation may rep-
resent a new mechanism to loose fat mass and may offer
new strategies to prevent the metabolic syndrome.
However, implications of the experimental fat blend
against obesity have to be investigated in future studies.
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